Clinical Research Directory
Browse clinical research sites, groups, and studies.
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
Sponsor: Zhujiang Hospital
Summary
To investigate the neoadjuvant chemoimmunotherapy regimen of Ivonescimab combined with chemotherapy (Paclitaxel plus Cisplatin/Carboplatin) for the treatment of locally advanced resectable oral squamous cell carcinoma and oropharyngeal squamous cell carcinoma.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
20
Start Date
2026-01-26
Completion Date
2028-08-30
Last Updated
2026-07-07
Healthy Volunteers
No
Conditions
Interventions
Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
Patients received two cycles of Ivonescimab combined with chemotherapy at a 3-week interval. The therapeutic regimen consisted of Ivonescimab (10 mg/kg) in combination with paclitaxel (135-175 mg/m²) plus cisplatin (80-120 mg/m²) or carboplatin (0.3-0.4 g/m²). Oral swabs and saliva samples were collected within 3 days prior to the initiation of the first cycle of Ivonescimab plus chemotherapy, within 3 days prior to the initiation of the second cycle, and within 3 days prior to surgery. Intraoperatively, tumor tissues and paracancerous tissues were harvested, and a 3 mm-thick section of the resected primary tumor lesion was obtained for pathological examination to investigate the tumor regression pattern.
Locations (2)
Department of Stomatology, Zhujiang Hospital, Southern Medical University, Haizhu District, Guangzhou
Guangzhou, Guangdong, China
Department of Stomatology, Zhujiang Hospital, Southern Medical University,Haizhu District
Guangzhou, Guangdong, China